Clearances for Autologous Blood Clot Product
RedDress Ltd (Pardes-Hanna, Israel) announced that its RD1 system received United States Food and Drug Administration 510(k) clearance. This clearance allows the company to market its system to the US market.
The system, an autologous blood clot product, is intended for use at point-of-care for the safe and rapid preparation of a whole blood clot from a small sample of a patient’s peripheral blood. This innovative product can be topically applied for the management of exuding cutaneous wounds and mechanically or surgically debrided wounds.
Visit www.reddress.co.il for more information.